India, July 3 -- Biocon Biologics(BBL), a fully integrated global biosimilars company and subsidiary of Biocon, today announced that the European Commission (EC) has granted marketing authorisation in the European Union (EU) for Vevzuo' and Evfraxy' biosimilars of Denosumab.Vevzuo' is authorised for the prevention of bone complications in adults with advanced cancer involving bone and the treatment of adults and skeletally mature adolescents with giant cell tumour (GCT) of bone.Evfraxy' is authorised for the treatment of osteoporosis in men and postmenopausal women, the treatment of bone loss linked to hormone ablation in men with prostate cancer at increased risk of fractures or treatment of bone loss associated with long-term systemic glu...